

## **Pharmacy Drug Policy Checklist**

POLICY NAME Rezdiffra (resmetirom) POLICY # 3374P

## Criteria

Coverage Criteria	
	Diagnosis of noncirrhotic nonalcoholic steatohepatitis (liver disease) (NASH/MASH)  • Diagnosis confirmed by one of the following: liver biopsy, elastography (MRE or VCTE), magnetic resonance imaging (MRI), serum or imaging biomarker (Fibroscan, NFS, ELF)
	Evidence of moderate to advanced liver fibrosis as evidenced by stages F2 to F3 fibrosis
	Age 18 years or older
	Prescribed by or in consultation with a hepatologist (liver doctor)
	Evidence of additional conditions such as prediabetes or type 2 diabetes, obesity, hypertension, etc
	Rezdiffra will be used in in addition to diet and exercise
Exclusion Criteria – Any of the following prevents coverage	
	Evidence of decompensated cirrhosis
	F1 or F4 fibrosis
	Evidence of significant alcohol consumption (defined as ≥20g/day for females or ≥30g/day for males)